Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

3.8K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
3.8K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
Menopause01:28

Menopause

3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
The Menstrual Cycle01:19

The Menstrual Cycle

3.1K
The menstrual cycle is a recurrent sequence of changes in the uterine endometrium, specifically its functional layer, the stratum functionalis. This cycle prepares the uterus for potential pregnancy. This cycle typically spans 21–35 days, averaging 28 days, and aligns with the ovarian cycle, regulated by fluctuating levels of ovarian hormones, primarily estrogen and progesterone.
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a...
3.1K
Menses Phase01:18

Menses Phase

1.0K
The uterine cycle begins with the menstrual phase, which is considered day one of the cycle and typically lasts about five days. This phase is characterized by the degeneration and shedding of the stratum functionalis, the functional layer of the endometrium.
When fertilization does not occur, the corpus luteum deteriorates, causing a significant drop in the levels of estrogen and progesterone in the body. This hormonal decrease triggers the release of prostaglandins, which cause the uterine...
1.0K
Secretory Phase01:19

Secretory Phase

2.1K
The secretory phase of the menstrual cycle, spanning from day 14 to 28 in a typical 28-day cycle, is a period of significant physiological changes in the female reproductive system. This phase commences immediately after ovulation and is characterized by the preparation of the endometrium for potential embryo implantation.
Following ovulation, the corpus luteum, a temporary endocrine structure, produces progesterone and estrogens. These hormones stimulate the growth and coiling of endometrial...
2.1K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Subcutaneous Forehead and Incidental Orbital Varices Diagnosed with MRI Under Sedation.

Journal of radiology case reports·2026
Same author

Evaluating and reducing environmental waste in oculofacial plastic procedures.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Floppy Eyelid Syndrome.

The New England journal of medicine·2026
Same author

Centers for Medicare & Medicaid Services Reimbursement Declines for Chalazion Incision and Drainage.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Effect of Subcutaneous Tranexamic Acid on Hemostasis and Ecchymosis in Oculofacial Procedures: A Double-Blind, Placebo-Controlled, Randomized Trial.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Exogenous Testosterone Use Increases the Risk of Central Serous Chorioretinopathy.

American journal of ophthalmology·2025
Same journal

Re: "A new surgical technique for excision of orbital cavernous hemangioma: a 15-year experience".

Orbit (Amsterdam, Netherlands)·2026
Same journal

Study of the toxic effect of benzalkonium chloride on epithelial cells of the lacrimal canaliculi.

Orbit (Amsterdam, Netherlands)·2026
Same journal

Orbital venous-flow malformations: is terminology complicating management in the <i>AI</i> era?

Orbit (Amsterdam, Netherlands)·2026
Same journal

Response to teprotumumab in thyroid eye disease patients of long duration and high clinical activity score.

Orbit (Amsterdam, Netherlands)·2026
Same journal

Incidentally discovered asymptomatic extramedullary plasmacytoma involving the orbit and dura.

Orbit (Amsterdam, Netherlands)·2026
Same journal

Warthin tumor of the lacrimal sac: a rare manifestation.

Orbit (Amsterdam, Netherlands)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 15, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.4K

甲状腺眼症（TED）治療薬テプロツムマブに関連する月経変化

Amina Malik1,2,3, Patrick J Hunt1,4, Tracy Lu1,5

  • 1Department of Ophthalmology, Houston Methodist Hospital, Houston, Texas, USA.

Orbit (Amsterdam, Netherlands)
|January 13, 2026
PubMed
まとめ
この要約は機械生成です。

甲状腺眼症（TED）治療薬テプロツムマブは、患者の55％に無月経を含む月経変化を引き起こしました。ほとんどの女性は治療後に正常な月経が再開しましたが、医療従事者の認識が重要です。

キーワード:
IGF-1甲状腺眼症無月経月経テプロツムマブ

さらに関連する動画

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
07:44

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

2.0K
Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

1.1K

関連する実験動画

Last Updated: Jan 15, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.4K
Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
07:44

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

2.0K
Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

1.1K

科学分野:

  • 内分泌学; 眼科学; 生殖医療

背景:

  • 甲状腺眼症（TED）は、眼窩に影響を与える自己免疫疾患です。テプロツムマブは、活動性のTED治療に使用される新しい生物学的製剤です。月経周期の不規則性は、全身療法における潜在的かつ過少報告されている副作用です。

研究 の 目的:

  • TEDの治療でテプロツムマブを受けている患者における月経周期の変化の発生頻度と特徴を決定すること。月経変化の種類とそのテプロツムマブ点滴との時間的関係を文書化すること。

主な方法:

  • 3つの施設（2020-2023年）でテプロツムマブ治療を受けた51人の女性患者の後ろ向きカルテレビュー。患者の人口統計、甲状腺の状態、ホルモン避妊薬の使用、および月経周期データ（種類、発症、期間）を含むデータを収集しました。臨床活動スコアおよび有害事象も記録されました。

主要な成果:

  • 患者の55％（28/51）が月経変化を経験しました。最も頻繁に見られた変化は無月経（75％）および稀発月経（21％）でした。月経不順は最初の点滴から約58日後に発生し、治療後の正常な月経再開までの平均期間は155日でした。最後の追跡調査までに正常な周期が再開しなかったのは14％でした。

結論:

  • 月経周期の障害は、TEDの女性におけるテプロツムマブ療法に関連する一般的な有害事象です。無月経および稀発月経が主な変化として観察されています。医療提供者は、テプロツムマブ治療中の月経不規則性の可能性について患者に助言する必要があります。